REC606

REC606 is a small molecule inhibitor of Mitogen-Activated Protein Kinase Kinase Kinase Kinase 4 (MAP4K4), currently under development by Recursion Pharmaceuticals. Discovered using Recursion's proprietary AI-driven phenomics platform, the compound is specifically designed to target the MAP4K4 pathway, which plays a critical role in mediating cell death and inflammatory responses in various tissues. The primary therapeutic focus for REC606 is cardiovascular disease, particularly the mitigation of damage following myocardial infarction and ischemia-reperfusion injury. By inhibiting MAP4K4, REC606 aims to protect cardiomyocytes from apoptosis, thereby preserving cardiac function and reducing infarct size. The program represents an application of Recursion's automated discovery approach to identify novel treatments for high-unmet-need conditions in the cardiovascular space.